大腸癌の対外診断用スクリーニング検査：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 12
3 Competitive Assessment 13
3.1 Overview 13
3.2 Fecal Occult Blood Tests 13
3.2.1 Guaiac Fecal Occult Blood Stool Tests 13
3.2.2 Lateral Flow Immuno-Fecal Occult Blood Tests 17
3.2.3 Readers 24
3.2.4 Immuno-FOB Test ELISA 27
3.2.5 Immuno-FOB Agglutination Tests 30
3.3 CRC DNA Screening Tests 40
3.3.1 Panel DNA Tests 40
3.3.2 Methylated Gene Testing 50
3.4 Other Biomarker Tests 59
3.4.1 Overview 59
3.4.2 Tumor M2-PK Stool Test/2-in-1 Quick Test 59
3.4.3 Transferrin Assays 61
4 Pipeline Products 63
4.1 Overview 63
4.2 Pipeline by Phases in Development 63
4.3 Pipeline Product Profiles 65
4.3.1 BST1 CRC Assay 65
4.3.2 Cologic 66
4.3.3 ColoGuard 68
4.3.4 Colon Cancer BEC Test 72
4.3.5 Colon MarCare Plex 73
4.3.6 Colox 76
4.3.7 CRC Bacterial Signature Assay 78
4.3.8 CRC Breath Test 79
4.3.9 Epi proColon 82
4.3.10 ExiQon MicroRNA Test 88
4.3.11 Gemini CRC Biomarker Assay 91
4.3.12 GenomicTree Methylated DNA Test 92
4.3.13 Measure Fecal Occult Blood Test 94
4.3.14 Metabiomics CRC Test 97
4.3.15 MiR-21 Test 99
4.3.16 Oncolite CR 101
4.3.17 PanC-Dx 103
5 Current and Future Players 106
5.1 Overview 106
5.2 Trends in Corporate Strategy 107
5.3 Company Profiles 107
5.3.1 Abbott Molecular 107
5.3.2 Alere 109
5.3.3 Beckman Coulter 112
5.3.4 Biomarcare Technologies 113
5.3.5 Companion Dx 115
5.3.6 Eiken Chemical 116
5.3.7 Epigenomics 119
5.3.8 Exact Sciences 124
5.3.9 ExiQon 128
5.3.10 Fujirebio (Miraca Holdings) 130
5.3.11 GeneNews 133
5.3.12 GenomicTree 134
5.3.13 Immunostics 136
5.3.14 Kyowa Medex 139
5.3.15 MDx Health (was OncoMethylome) 141
5.3.16 Merck Millipore 143
5.3.17 Metabiomics 145
5.3.18 Mode Diagnostics 147
5.3.19 Oncocyte (Bio Time) 149
5.3.20 Quest Diagnostics 151
5.3.21 R-Biopharm 155
5.3.22 Randox Laboratories 158
5.3.23 ScheBo Biotech 159
5.3.24 SciMarket Technologies 162
5.3.25 Siemens Healthcare 163
5.3.26 Signature Diagnostics 166
5.3.27 Sysmex 167
5.3.28 Veda Lab 169
6 Appendix 172
6.1 Abbreviations 172
6.2 Bibliography 175
6.3 Research Methodology 205
6.3.1 Coverage 205
6.3.2 Secondary Research 206
6.4 Physicians and Specialists Included in this Study 207
6.5 Primary Research 208
6.6 About the Authors 209
6.6.1 Analysts 209
6.6.2 Global Head of Healthcare 210
6.7 About GlobalData 211
6.8 Disclaimer 211